This is contrary to the persistent perception that RP-ILD in IIM is closely associated with inflammatory cytokine storms like severe COVID-19 [36, 37], so it is cautious to assume that high circulating IL-6 was not a hallmark of RP-ILD, much less simply an indication for the utilization of tocilizumab, which is important for clinical practice. This evidence concerns the gene IL6 and interstitial lung disease.